JAGX · Jaguar Health, Inc.

Jaguar Health, Inc. faces critical Nasdaq compliance pressure after receiving a decision letter on April 24, 2026, from the Nasdaq Hearings Panel following a hearing on April 7, 2026. The Panel granted a conditional extension to demonstrate compliance with Listing Rule 5550(a)(2) by achieving a $1.00 closing bid price for at least 10 consecutive business days by May 15, 2026, with possible deferral up to 20 business days. This stems from prior non-compliance where the stock closed below $1.00 for 30 consecutive days, and ineligibility for standard grace periods due to recent reverse splits. To address this, stockholders at the April 20, 2026 Special Meeting approved the Eleventh Amendment to the Certificate of Incorporation, authorizing a reverse split ratio between 1-for-15 and 1-for-150. The Board selected 1-for-35, filing the amendment on April 24, 2026, effective April 30, 2026. This reclassifies every 35 pre-split shares into one post-split share, proportionally adjusting options, warrants, and equity plan reserves without altering authorized shares. No action is needed for street-name holders, with Equiniti Trust Company, LLC as exchange agent. Failure to meet bid price terms risks delisting, with Panel oversight until September 1, 2026, underscoring heightened listing vulnerability for investors.